SCYNEXIS SCYX 深 沪
已收盘 08-15 16:00:00 美东时间
0.8399
+0.038
+4.78%
华盛通- 最 高0.8499
- 今 开0.80
- 成交量 10.62万股
- 最 低 0.7945
- 昨 收 0.8016
- 总市值 3277.31万
- 52周最高 1.6866
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 0.66
- 委 比 75.69%
- 总股本 3902.03万
- 历史最高 150.00
- 量 比 0.61
- 振 幅 6.91%
- 历史最低 0.66
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SCYNEXIS Q2 EPS $(0.14) Beats $(0.19) Estimate, Sales $1.364M Beat $154.000K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26.32 percent. This is a 53.33 percent increase over losses of $(0.30) per share from the same
08-14 04:34
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS reported Q2 2025 financial results, including revenue of $1.4M from the GSK License Agreement and a net loss of $6.9M. The company is progressing its Phase 3 MARIO study with GSK, triggering milestone payments despite disputes, and plans to transfer the BREXAFEMME NDA to GSK by year-end. SCYNEXIS anticipates Phase 1 data for SCY-247 in Q3 2025 and ended Q2 with $46.5M in cash, projecting a cash runway into Q4 2026. The company also saw a...
08-13 20:30
SCYNEXIS Holds Annual Meeting, Re-elects Directors
SCYNEXIS ( ($SCYX) ) just unveiled an update. On June 25, 2025, SCYNEXIS, Inc. ...
07-02 04:41
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
SCYNEXIS announced the resumption of patient dosing in its Phase 3 MARIO study for oral ibrexafungerp after the FDA lifted its clinical hold. This restart triggers a $10 million milestone payment from GSK, with an additional $20 million due in six months. Despite the milestone disputes between SCYNEXIS and GSK, patient enrollment has resumed, with nearly 25% of projected patients already enrolled. The study aims to evaluate ibrexafungerp as a ste...
05-28 12:30
SCYNEXIS Faces Challenges Amidst Antifungal Developments
SCYNEXIS Inc ( ($SCYX) ) has released its Q1 earnings. Here is a breakdown of t...
05-20 11:52
SCYNEXIS shares are trading lower following Q1 reported financial results.
SCYNEXIS shares are trading lower following Q1 reported financial results.
05-16 21:13
SCYNEXIS Q1 EPS $(0.11) Beats $(0.17) Estimate, Sales $257.00K Beat $205.50K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 35.29 percent. This is a 1200 percent decrease over earnings of $0.01 per share from the same
05-16 04:50
FDA计划逐步淘汰动物实验 首个基因替代疗法药物国内上市 映恩生物即将在港股上市 | 医药投向标
① 国家药监局公开征求医疗器械分类规则意见；国家药监局发文支持境外已上市药品尽早用于临床。 ② FDA计划逐步淘汰动物实验。 ③ 锦波生物国内首个中面部重组Ⅲ型“胶原蛋白填充剂”获批；国内首个基因替代疗法药物上市。 ④ 觅投克生物、睿健医药完成融资。
04-14 07:40
阳光德美助力翰森制药抗真菌新药艾瑞芬净国内获批！
2025年4 月 8 日，翰森制药申报的艾瑞芬净（Ibrexafungerp Tablets；研发代号：HS-10366）获批上市，用于成年和初潮后女性外阴阴道...
04-10 14:07
